The Firm represented the underwriters, J.P. Morgan Securities LLC, Citigroup Global Markets Inc., Jefferies LLC and Leerink Partners LLC, in connection with an offering by Zai Lab Limited (“Zai Lab”) of 7,500,000 American depositary shares (“ADSs”), each representing one ordinary share of Zai Lab, at a public offering price of $20 per ADS. Zai Lab received approximately $141 million in net proceeds from the offering. The offering closed on September 10, 2018. The underwriters have a 30-day option to purchase up to 1,125,000 additional ADSs.
Zai Lab is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world.
The Simpson Thacher team for the transaction included Art Robinson, Hui Lin, John O’Connell, Meaghan Krupa, Tracy Peng and Stephan Bradley (Capital Markets – New York); Celia Lam and Carol Chan (Capital Markets – Hong Kong); Tyler Robbins (Tax); Adam Cohen (Benefits); Michael Isby (Environmental); Lori Lesser and Lawrence Huang (IP); and Jennie Getsin (Blue Sky/FINRA).